Human and Improved Murine Monoclonal Antibodies Against CD22
Background:
The National Cancer Institute's
Nanobiology Program is seeking statements of capability or interest
from parties interested in collaborative research to further
develop, evaluate, or commercialize human monoclonal antibodies
expressed in types of lymphoma.
CD22 is a cell surface protein that is highly expressed in a number
of B cell lymphomas, such as hairy cell leukemia (HCL),
non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Several clinical trials using anti-CD22 antibodies are ongoing.
However, all of these antibodies are murine in nature, and have the
potential to elicit immune responses in patients. The
immunogenicity may adversely affect the ability to provide patients
with repeated doses of a therapeutic comprising the antibody,
limiting the clinical application of those
therapeutics.
Technology:
In order to address the issue of
immunogenicity in patients, NIH inventors have generated two
anti-CD22 antibodies of human origin. Each antibody has the ability
to recognize CD22 on the surface of Raji cells. Thus, these
antibodies represent an attractive alternative to the murine
anti-CD22 antibodies currently being tested in clinical trials.
Additionally, the inventors have generated a modified murine
anti-CD22 antibody with increased binding affinity and solubility.
This antibody could also be a suitable alternative for the murine
antibodies currently available.
This invention has numerous potential applications including use as
an antibody or immunotoxin therapeutic for B cell lymphomas or as a
diagnostic for the detection of CD22 positive tumors. Because this
technology describes fully human antibodies, it could provide
viable alternatives to current humanized or chimeric anti-CD22
antibodies in the treatment of CD22 related diseases.
Value Proposition
Solution:
- Fully-human antibody and with high affinity that may have
reduced immunogenicity, thereby allowing repeated dosing
- Modified murine anti-CD22 antibody with increased binding
affinity and solubility
- Ability to develop antibody or immunotoxin therapeutics for B
cell lymphomas
- Ability to develop antibody or immunotoxin diagnostics for the
detection of CD22-positive tumors
Further R&D
Needed:
- Conjugate antibodies with various cancer drugs and drug-loaded
nano-liposomes for targeted delivery
- Test antibodies in combination with other clinically-approved
antibodies.
R&D Status:
Pre-clinical,
in vitro. In vivo are planned.
IP Status:
U.S. Provisional Application No. 61/042,329 filed 04 April 2008.
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #658 JH
Posted 05/08/2008
This opportunity is also listed under the following categories: